Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives

Thrombosis Research

Volumn 116, Issue 3, 2005, Pages 265-271

  Do, Yee H ^a   Gifford Moore, Donetta S ^a   Beight, Douglas W ^a   Rathnachalam, Radhakrishnan ^a   Klimkowski, Valentine J ^a   Warshawsky, Alan M ^a   Lu, Deshun ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Fibrinolysis; TAFI; Thrombosis

Indexed keywords

CYSTEINE DERIVATIVE; GLYCYLCYSTEINE; GLYCYLGLYCYLCYSTEINE; GUANIDINYLCYSTEINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOT LYSIS; CONCENTRATION RESPONSE; DRUG MECHANISM; FIBRINOLYSIS; INHIBITION KINETICS; PRIORITY JOURNAL;

CARBOXYPEPTIDASE U; CYSTEINE; FIBRINOLYSIS; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20144381372     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.12.023     Document Type: Article

References (27)

1. L. Bajzar, R. Manuel, and M.E. Nesheim Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor J. Biol. Chem. 270 24 1995 14477 14484
2. L. Bajzar, M. Nesheim, J. Morser, and P.B. Tracy Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor J. Biol. Chem. 273 5 1998 2792 2798
3. W. Wang, M.B. Boffa, L. Bajzar, J.B. Walker, and M.E. Nesheim A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor J. Biol. Chem. 273 42 1998 27176 27181
4. G.J. Broze, and D. Higuchi Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma Blood 88 10 1996 3815 3823
5. C.J. Refino, L. De Guzman, D. Schmitt, R. Smyth, S. Jeet, and M.T. Lipari Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis Fibrinolysis Proteolysis 14 5 2000 305 314
6. N.H. van Tilburg, F.R. Rosendaal, and R.M. Bertina Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis Blood 95 9 2000 2855 2859
7. G.J. Brouwers, F.W. Leebeek, M.W. Tanck, J. Wouter Jukema, C. Kluft, and M.P. de Maat Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris Thromb. Haemost. 90 2003 92 100
8. J. Montaner, M. Ribo, J. Monasterio, C.A. Molina, and J. Alvarez-Sabin Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke Stroke 34 4 2003 1038 1040
9. Y. Hori, E.C. Gabazza, Y. Yano, A. Katsuki, K. Suzuki, and Y. Adachi Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in Type 2 diabetic patients J. Clin. Endocrinol. Metab. 87 2 2002 660 665
10. D. Eaton, B. Malloy, S. Tsai, W. Henzel, and D. Drayna Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma J. Biol. Chem. 266 32 1991 21833 21838
11. P.J. Barbosa Pereira, S. Segura-Martin, B. Oliva, C. Ferrer-Orta, F.X. Aviles, and M. Coll Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI) J. Mol. Biol. 321 2002 537 547
12. Y. Muto, K. Suzuki, E. Sato, and H. Ishii Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats Eur. J. Pharmacol. 461 2-3 2003 181 189
13. M.O. Polla, L. Tottie, C. Norden, M. Linschoten, D. Musil, and Trumpp-Kallmeyer Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa) Bioorg. Med. Chem. 12 5 2004 1151 1175
14. J.C. Barrow, P.G. Nantermet, S.R. Stauffer, P.L. Ngo, M.A. Steinbeiser, and S.S. Mao Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics J. Med. Chem. 46 2003 5294 5297
15. T.H. Plummer Jr., and M.Y. Hurwitz Human plasma carboxypeptidase N. Isolation and characterization J. Biol. Chem. 253 11 1978 3907 3912
16. R. Skidgel Human carboxypeptidase N: lysine carboxypeptidase Methods Enzymol. 248 1995 653 663
17. D.T. Berg, B. Gerlitz, J. Shang, T. Smith, P. Santa, and M.A. Richardson Engineering the proteolytic specificity of activated protein C improves its pharmacological properties Proc. Natl. Acad. Sci. 100 8 2003 4423 4428
18. P. Henderson A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors Biochem. J. 127 1972 321 333
19. T.H. Plummer Jr., and M.T. Kimmel An improved spectrophotometric assay for human plasma carboxypeptidase N1 Anal. Biochem. 108 1980 348 353
20. L.M. Peterson, B. Holmquist, and J.L. Bethune A unique activity assay for carboxypeptidase A in human serum Anal. Biochem. 125 1982 420 426
21. G.F. Smith, R.T. Shuman, T.J. Craft, D.S. Gifford, K.D. Kurz, and N.D. Jones A family of arginal thrombin inhibitors related to efegatran Semin. Thromb. Hemost. 22 2 1996 173 183
22. D.M.F. van Aalten, C.R. Chong, and L. Joshua-Tor Crystal structure of carboxypeptidase A complexed with d-cysteine at 1.75 A-inhibitor-induced conformational changes Biochemistry 39 2000 10082 10089
23. QUANTA. p. version 98.1111, Accelrys Inc., San C.A. Diego, 92121.
24. CHARMM, v., Accelrys Inc., San C.A. Diego, 92121.
25. B.R. Brooks, R.E. Cruccoleri, B.D. Olafson, D.J. States, S. Swaminathan, and M. Karplus CHARMM: a program for macromolecular energy, minimization and dynamics calculations J. Comput. Chem. 4 1983 187 217
26. M.A. Ondetti, M.E. Condon, J. Reid, E.F. Sabo, H.S. Cheung, and D.W. Cushman Design of potent and specific inhibitors of carboxypeptidases A and B Biochemistry 18 1979 1427 1430
27. D.W.D. Beight, Y.H. Do, D. Gifford-Moore, R.W. Harper, V.J. Klimkowski, and D. Lu Design of peptide-based inhibitors of thrombin activated fibrinolysis inhibitor (TAFI) 226th ACS National Meeting, New York, N.Y., United States 2003 (September 7-11) MEDI-086